Metabolic Dysfunction-Associated Steatohepatitis | Disease Landscape & Forecast | G7 | 2024
The market for metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has great untapped potential owing to the disease’s high prevalence and limited number of approved treatment options (with resmetirom [Rezdiffra] approved only in the United States). Evidence shows that the disease burdens healthcare systems, mainly due to the higher risk of heart disease, liver failure, and liver transplants. Despite guidelines recommending certain medications to manage comorbidities, prescribing is usually limited to specialists treating patients with more-advanced disease. However, with more education about the disease, development of less-invasive diagnostic tools, and availability of approved medical therapies, diagnosis and treatment rates are expected to rise. Over the 2024-2034 forecast period, the MASH market will see the launch of multiple agents from a rich pipeline of emerging therapies, fueling massive market expansion.
Questions answered:
- What is the prevalence of MASH, and what is driving its growth?
- How is MASH managed? With no approved medications, how do physicians use current medications off-label to treat the disease?
- How has the launch of Madrigal Pharmaceuticals’ Rezdiffra affected the treatment paradigm in the United States? After its launch, how will the therapy be received in the European markets?
- Which emerging therapy will gain the greatest share in the emerging branded therapy market?
- What do key opinion leaders think about the emerging therapies such as Novo Nordisk’s semaglutide, Inventiva Pharma’s lanifibranor, Eli Lilly’s tirzepatide, and Akero’s efruxifermin?
CONTENT HIGHLIGHTS
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
- Primary research: 26 country-specific interviews with thought-leading gastroenterologists and hepatologists. Supported by survey data collected for this and other Clarivate research.
- Epidemiology: Diagnosed prevalence of NASH by country; population segmentation by stage of fibrosis.
- Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
- Market forecast features: 10-year, annualized, drug-level sales and patient share of key NASH therapies through 2033, segmented by brands and epidemiological subpopulations.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
KEY FEATURES
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
